Overview

A class action lawsuit has been filed against Avantor, Inc. (“Avantor” or the “Company”) and certain of the Company’s former and current senior executive officers alleging violations of the federal securities laws. The Company’s common stock trades on the New York Stock Exchange under the ticker symbol “AVTR.”

The Avantor class action lawsuit was brought on behalf of all persons and entities who purchased or otherwise acquired Avantor common stock between March 5, 2024, and October 28, 2025, both dates inclusive, (the “Class Period”).

Avantor is a life science tools company that provides scientific products and services for customers in a variety of industries. The Company reports its financial results in two business segments: Laboratory Solutions (which accounts for approximately two-thirds of the Company’s net sales); and Bioscience Production.

The lawsuit alleges that Avantor and its executives misled investors about the company’s competitive position and the impact of rising competition on its business performance. During the class period, defendants made repeated public statements emphasizing Avantor’s strong competitive standing, digital capabilities, and ability to maintain market share. For example, during an earnings call on July 26, 2024, when asked about potential market share losses to competitors, a company defendant—then serving as President and Chief Executive Officer—assured investors that Avantor’s laboratory business “stacks up well against every number,” that the company continued to “enhance our position,” and that management was “really confident in our value proposition and competitive position.” Defendants repeatedly reinforced this narrative, claiming that Avantor’s operational advantages would allow it to perform well despite broader market challenges.

According to the lawsuit, these statements were materially false and misleading because Avantor was, in fact, struggling to maintain its competitive position and was already experiencing negative effects from increased competition. The company’s true performance began to emerge on April 25, 2025, when Avantor reported disappointing first-quarter 2025 financial results, reduced its full-year guidance, and announced that the company’s chief executive officer would be stepping down. Defendants attributed the weak results to “increased competitive intensity.” Following this disclosure, Avantor’s stock price fell $2.57 per share, or more than 16.5%, from $15.50 on April 24, 2025, to $12.93 on April 25, 2025.

On August 1, 2025, Avantor reported another set of disappointing results for the second quarter of 2025, including a year-over-year decline in net sales and a further reduction of its 2025 guidance. The company now projected organic revenue growth between -2% and 0%, again attributing the results to “increased competitive intensity.” Defendants also acknowledged that they did not expect market conditions to improve through the remainder of the year. In response, Avantor’s stock fell another $2.08 per share, or more than 15%, from $13.44 on July 31, 2025, to $11.36 on August 1, 2025.

The company’s difficulties deepened later in the year. On October 29, 2025, Avantor announced weak third-quarter 2025 results, reporting a -5% organic revenue decline—below prior guidance—and a net loss of $712 million. Defendants attributed the loss largely to a $785 million non-cash goodwill impairment charge, which they admitted stemmed from “competitive pressures” that had significantly impacted margins. They further disclosed that Avantor had lost several large customer accounts. Following this announcement, the company’s stock fell $3.50 per share, or more than 23%, from $15.08 on October 28, 2025, to $11.58 on October 29, 2025.

The lawsuit further alleges that, throughout the class period, defendants misrepresented Avantor’s competitive strength and concealed the extent to which the company was being adversely affected by intensified competition. As a result, investors were misled about the company’s true business condition and outlook, and when the truth emerged through a series of disappointing earnings disclosures, Avantor’s stock price declined sharply, causing significant losses to investors.

*          *          *

If you purchased or otherwise acquired Avantor common stock between March 5, 2024, and October 28, 2025, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as lead plaintiff in the Avantor class action lawsuit is December 29, 2025.